Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCAR-AIO in relapsed/refractory autoimmune diseases
NCT06866080Phase 1Withdrawn
- Sponsor
- Legend Biotech Corporation
- Start
- Jun 2025
- Primary completion
- Jun 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LCAR-AIO in systemic lupus erythematosus (SLE), Antineutrophil cytoplasmic antibody-associated vasculitis (AAV), systemic sclerosis (SSc) and 1 more, sponsored by Legend Biotech Corporation. Primary endpoints: Systemic Lupus Erythematosus Disease Activity Index 2000 at 104 weeks, Birmingham Vasculitis Activity Score at 104 weeks and 4 more. Planned start Jun 2025; status: withdrawn.
02
Drugs
LCAR-AIO
03
Conditions
systemic lupus erythematosus (SLE)Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)systemic sclerosis (SSc)idiopathic inflammatory myopathy (IIM)
Beyond the preview
Go deeper on NCT06866080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06866080.